Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces positive Tekturna HCT data

Novartis announces positive Tekturna HCT data

20th May 2008

Novarits has announced new data for Tektruna HCT showing that it is twice as effective at reducing blood pressure than HCT alone.

Tekturna HCT is a single-tablet combination of the diuretichydrochlorothiazide (HCT) and direct renin inhibitorTekturna (aliskiren).

Data presented to the American Society of Hypertension show that while Tekturna HCT and Tekturna both provide effective blood pressure lowering with good tolerability.

Furthermore, blood pressure reductions provided by Tekturna were found to last beyond 24 hours.

The firm reports that many patients need more than one drug to reach their target blood pressure, with combination therapies in one tablet potentially making treatment more convenient.

Alan Gradman, of the division of cardiovascular diseases at the Western Pennsylvania Hospital in Pittsburgh, US, said: “High blood pressure, or hypertension, is a serious global problem and we are clearly in need of treatments to help patients reach their target blood pressure levels.”

He added that data shows that Tekturna HCT is a convenient and effective for patients with high blood pressure who are at a higher risk of stroke, heart failure and heart attack.

In March 2007, Novartis announced the results of a clinical study showing that patients administered with Tekturna in combination Diovan (valsartan) saw a higher reduction in blood pressure than those administered with one or the other compound.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.